Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

(S)-crizotinib

🥰Excellent
Catalog No. T6357Cas No. 1374356-45-2
Alias ent-crizotinib

(S)-crizotinib (ent-crizotinib) (IC50 of 72 nM), an effective MTH1 (NUDT1) inhibitor, is the (S)-enantiomer of crizotinib.

(S)-crizotinib

(S)-crizotinib

🥰Excellent
Purity: 99.89%
Catalog No. T6357Alias ent-crizotinibCas No. 1374356-45-2
(S)-crizotinib (ent-crizotinib) (IC50 of 72 nM), an effective MTH1 (NUDT1) inhibitor, is the (S)-enantiomer of crizotinib.
Pack SizePriceAvailabilityQuantity
2 mg$39In Stock
5 mg$64In Stock
10 mg$97In Stock
25 mg$162In Stock
50 mg$239In Stock
100 mg$372In Stock
1 mL x 10 mM (in DMSO)$70In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "(S)-crizotinib"

Select Batch
Purity:99.89%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
(S)-crizotinib (ent-crizotinib) (IC50 of 72 nM), an effective MTH1 (NUDT1) inhibitor, is the (S)-enantiomer of crizotinib.
Targets&IC50
MTH1:72 nM
In vitro
In the SW480 colorectal cancer model, daily oral administration of 50mg/kg (S)-Crizotinib effectively inhibits tumor growth.
In vivo
(S)-crizotinib activates DNA repair mechanisms in human colorectal cancer cells by inhibiting MTH1, thereby disrupting nucleotide pool homeostasis and further inducing an increase in DNA single-strand breaks.
Kinase Assay
MTH1 catalytic assay: Half-maximal inhibitory concentrations (IC50) are determined using a luminescence-based assay with some minor modifications. Briefly, serial dilutions of compounds are dissolved in assay buffer (100?mM Tris-acetate pH?7.5, 40?mM NaCl and 10?mM Mg(OAc)2 containing 0.005% Tween-20 and 2?mM dithiothreitol (DTT). Upon addition of MTH1 recombinant protein (final concentration 2?nM), plates are incubated on a plate shaker for 15?min at room temperature. After addition of the substrate dGTP (final concentration 100?μM), 8-oxo-dGTP (final concentration 13.2?μM), or 2-OH-dATP (final concentration 8.3?μM) the generation of pyrophosphate (PPi) as a result of nucleotide triphosphate hydrolysis by MTH1 is monitored over a time course of 15?min using the PPi Light Inorganic Pyrophosphate Assay kit. IC50 values are determined by fitting a dose-response curve to the data points using nonlinear regression analysis using the GraphPad Prism software.
Cell Research
One day before treatment, cells are seeded per well in six-well plates and incubated for 24 h. The next day DMSO (equal to highest amount of compound dilution, maximum 0.2%) or compounds in increasing concentrations were added and cells incubated at 37 °C, 5% CO2, for 7-10 days. After washing with PBS, cells are fixed with ice-cold methanol, stained with crystal violet solution (0.5% in 25% methanol) and left to dry overnight. For quantification of results, ultraviolet absorbance of crystal violet is determined at 595 nm following solubilisation by 70% ethanol. Data are analysed using nonlinear regression analysis using the GraphPad Prism software. (Only for Reference)
Aliasent-crizotinib
Chemical Properties
Molecular Weight450.34
FormulaC21H22Cl2FN5O
Cas No.1374356-45-2
SmilesC[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl
Relative Density.1.47 g/cm3 (Predicted)
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
1eq. HCl: 9 mg/mL (20 mM)), Heating is recommended.
DMSO: 22.5 mg/mL (50 mM)
Solution Preparation Table
1eq. HCl/DMSO
1mg5mg10mg50mg
1 mM2.2205 mL11.1027 mL22.2054 mL111.0272 mL
5 mM0.4441 mL2.2205 mL4.4411 mL22.2054 mL
10 mM0.2221 mL1.1103 mL2.2205 mL11.1027 mL
20 mM0.1110 mL0.5551 mL1.1103 mL5.5514 mL
DMSO
1mg5mg10mg50mg
50 mM0.0444 mL0.2221 mL0.4441 mL2.2205 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy (S)-crizotinib | purchase (S)-crizotinib | (S)-crizotinib cost | order (S)-crizotinib | (S)-crizotinib chemical structure | (S)-crizotinib in vivo | (S)-crizotinib in vitro | (S)-crizotinib formula | (S)-crizotinib molecular weight